Rynek i konsumenci · 19/04/2024

CPSC Exempts Baloxavir Marboxil Tablets from Child-Resistant Packaging Requirements

The Consumer Product Safety Commission is amending its regulation to exempt baloxavir marboxil tablets, marketed as XOFLUZA, from child-resistant packaging requirements in packages containing 80 mg or less of the drug, citing the product's non-toxic nature and lack of adverse human experience.